Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint

Vertex Pharmaceuticals (VRTX) reported strong Q3 2025 results, with adjusted EPS of $4.80 and revenues of $3.08 billion, both surpassing analyst estimates driven by robust sales of Trikafta/Kaftrio and new drug Alyftrek. Despite the overall beat and tightened full-year 2025 revenue guidance to $11.9-$12.0 billion, the stock declined 4% in after-hours trading due to disappointing sequential sales of its gene therapy Casgevy, which fell 44.4% to $16.9 million, signaling a slower-than-anticipated market uptake. While Vertex highlighted a rapidly advancing pipeline beyond its core CF franchise, the slow Casgevy launch and continued reliance on CF sales remain key investor considerations.

Analysis

Vertex Pharmaceuticals (VRTX) reported strong Q3 2025 results, with adjusted EPS of $4.80 surpassing estimates of $4.55 and total revenues of $3.08 billion beating the $3.04 billion consensus. Revenue grew 11% year-over-year, primarily driven by robust sales of Trikafta/Kaftrio ($2.65 billion, up 2.6% YoY) and the strong launch of Alyftrek, which generated $247.0 million, up from $156.8 million sequentially. This core CF franchise continues to be a significant revenue driver for the company.

Despite the overall earnings and revenue beat, VRTX shares declined 4% in after-hours trading, likely attributable to the disappointing sequential sales performance of Casgevy. Sales for the gene therapy fell 44.4% to $16.9 million, indicating a slower-than-expected market uptake for this critical new product, despite Vertex's expectation of over $100 million in Casgevy revenues for the year and significant growth in 2026.

The company tightened its full-year 2025 revenue guidance to $11.9-$12.0 billion, representing 8-9% growth, but also raised its combined adjusted R&D, AIPR&D, and SG&A expense guidance to $5.0-$5.1 billion to support new product launches like Journavx and pipeline acceleration. Vertex maintains a rapidly advancing mid-to-late-stage pipeline with five programs in pivotal development, including povetacicept for IgAN, which has completed phase III enrollment and is slated for a BLA submission by year-end 2025.

However, the article highlights ongoing concerns regarding Vertex's dependence on its CF franchise, which shows signs of slightly slowing growth, and recent pipeline setbacks in its pain program. The strong performance of established products and promising pipeline assets are juxtaposed with the slow initial uptake of Casgevy and increasing operational expenses, contributing to a mixed sentiment despite headline beats.

Key Decisions for Investors

• Investors should closely monitor the sales trajectory and market penetration of Casgevy in upcoming quarters, as its initial slow uptake has negatively impacted market sentiment despite overall strong financial performance.
• Evaluate the long-term growth potential of Vertex's diverse late-stage pipeline, particularly the five pivotal programs, against the backdrop of increasing R&D expenses and the company's current reliance on its core CF franchise.
• Consider the implications of the tightened revenue guidance and increased expense outlook on future profitability and growth, especially given the stock's year-to-date underperformance relative to the industry.